Report Overview
The Global Human Growth Hormone Market size is expected to be worth around US$ 19.8 Billion by 2034, from US$ 5.9 Billion in 2024, growing at a CAGR of 12.7% during the forecast period from 2025 to 2034. North America held a dominant market position, capturing more than a 39.2% share and holds US$ 2.4 Billion market value for the year.
The global Human Growth Hormone (HGH) market is witnessing significant growth, fueled by advancements in biotechnology, increasing awareness of growth-related disorders, and the rising adoption of growth hormone therapies. Human growth hormone, or somatotropin, plays a vital role in promoting growth and development and is extensively utilized to address conditions such as growth hormone deficiency (GHD), Turner syndrome, Prader-Willi syndrome, chronic kidney diseases, and other related disorders. The market is further bolstered by the expanding use of hGH in non-growth-related areas, including muscle-wasting diseases and aging-related hormonal therapies.
- According to NIH, the prevalence of Turner syndrome among all pregnancy outcomes is 3.2 cases per 10,000 live female births.
- Turner syndrome occurs in approximately 1 in 2,000 to 1 in 2,500 individuals assigned female at birth.
- As per NIH, the estimated prevalence of Prader-Willi syndrome (PWS) ranges from 1 in 10,000 to 1 in 30,000 across various populations.
Key growth drivers include the growing incidence of growth disorders, increased emphasis on pediatric care, and continuous innovations in recombinant DNA technology. Emerging solutions, such as long-acting growth hormone formulations and needle-free delivery systems, are enhancing patient compliance and broadening treatment adoption.
Additionally, the off-label use of hGH for anti-aging and athletic performance is contributing to market growth, though it poses regulatory challenges. Challenges such as high treatment costs, stringent regulatory frameworks, and potential risks associated with long-term hormone use could hinder market progress.
Leading players, including Pfizer, Novo Nordisk, Eli Lilly, and Sandoz, are focusing on strategic collaborations, R&D investments, and geographical expansion to strengthen their market presence. The global human growth hormone market is positioned for sustained growth, underpinned by technological advancements and the expansion of therapeutic applications.
Global Human Growth Hormone Market, Global Analysis, 2020-2024 (US$ Billion)
| Distribution Channel | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| North America | 1.8 | 1.9 | 2.0 | 2.2 | 2.4 |
| Europe | 1.1 | 1.1 | 1.2 | 1.3 | 1.5 |
| Asia Pacific | 0.8 | 0.9 | 1.0 | 1.1 | 1.2 |
Key Regions and Countries
- North America
- US
- Canada
- Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherland
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
Key Players Analysis
The global human growth hormone (HGH) market is highly competitive, characterized by the presence of established players and emerging biosimilar manufacturers. Key players such as Pfizer, Novo Nordisk, Merck KGaA, and Eli Lilly dominate the market with a strong portfolio of recombinant HGH products and long-acting formulations. The rising adoption of biosimilars is intensifying competition, particularly in price-sensitive regions.
Companies are focusing on strategic collaborations, R&D investments, and technological advancements in delivery systems to maintain a competitive edge. Additionally, market players are expanding their geographic presence and targeting new therapeutic applications to capitalize on the growing demand for HGH therapies.
Top Key Players in the Human Growth Hormone Market
- Ferring Pharmaceuticals
- Pfizer Inc.
- Ascendis Pharma
- Eli Lilly and Company
- Novo Nordisk AS
- Merck KGaA
- Teva Pharmaceutical Industries Ltd.
- AnkeBio Co. Ltd
- Genetech Inc.
- Sandoz UK
Recent Developments
- In September 2023, Ascendis Pharma A/S introduced SKYTROFA® (lonapegsomatropin) in Germany. This marked the launch of the growth hormone product, which has received approval within the European Union for the treatment of children and adolescents aged 3 to 18 years. It is intended for those who experience growth failure resulting from inadequate natural growth hormone secretion, a condition known as growth hormone deficiency (GHD).
- In January 2022, Pfizer Inc. and OPKO Health, Inc. made an announcement regarding the response from the U.S. Food and Drug Administration concerning the Biologics License Application (BLA) for somatrogon. Somatrogon is a long-acting recombinant human growth hormone under investigation for its potential use in the cure of growth hormone deficiency (GHD) in pediatric patients. Pfizer currently reviewing the feedback provided by the FDA and intends to collaborate with the organization to chart a suitable course of action.